Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study Razavi-Shearer et al.

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study Razavi-Shearer et al. Oct 2023 Volume 8Number 10p861-954 Food as a global health and social priority The Lancet Gastroenterology & Hepatology https://www.thelancet.com/journals/langas/issue/current a.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00165-0/fulltext?dgcid=hubspot_email_jcr23_langas&utm_campaign=jcr23&utm_medium=email&_hsmi=272336523&_hsenc=p2ANqtz-8e51IPnqk9yAttwB3VqrE3-Oum7iKZr6g6yKml75iU_aLsyYbFQHFGlUdj6Agj5FhuvmPQH2fQJMVKfvUNjl6fE1GU-w&utm_content=272336523&utm_source=hs_automation b.Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial Open Access https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00010-9/fulltext?dgcid=hubspot_email_jcr23_langas&utm_campaign=jcr23&utm_medium=email&_hsmi=272336523&_hsenc=p2ANqtz-_IjcYW2kN57txThqkPq6fMBjeJSkpJvTAvuxyaG-XEc_iaXXySe6A7NhRFE_nvpxxuawB_qFk3XfzeW8cycn1Fx_xP9A&utm_content=272336523&utm_source=hs_automation c.Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00197-8/fulltext?dgcid=hubspot_email_jcr23_langas&utm_campaign=jcr23&utm_medium=email&_hsmi=272336523&_hsenc=p2ANqtz-97Z3py5_Ez-NzrRheFeqHeS85atIr0RmZfhNGTV2gGX_wd9h6XNW9qqyoFdMjIKkOshLcyXdGMqBGJwZ9eJacgqo_GEg&utm_content=272336523&utm_source=hs_automation d.Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00427-7/fulltext?dgcid=hubspot_email_jcr23_langas&utm_campaign=jcr23&utm_medium=email&_hsmi=272336523&_hsenc=p2ANqtz-_bSY-_7rK0WzuP3zgVpy_qcbOA1ErB0gU3gBdLRGClgQ8_AVaUeKC-5op1D06NlPj05AE6t1hjY-kmVGyGrSZuSmzvFA&utm_content=272336523&utm_source=hs_automation e.Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialThe prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00385-5/fulltext?dgcid=hubspot_email_jcr23_langas&utm_campaign=jcr23&utm_medium=email&_hsmi=272336523&_hsenc=p2ANqtz-9GV6alyyalvL-YxWV2sTYDbXRU8g0NItNaESfTvtyYfx3PFXcE8kmM1bGXVDRBWwd6YkMgMluG9HTr_FKZ99YcK-J7Uw&utm_content=272336523&utm_source=hs_automation